GlobeNewswire

Aino Health AB (publ): The Offer in Aino Health AB (publ) heavily oversubscribed

Dela

PRESS RELEASE
December 9, 2016

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO NEWS DISTRIBUTORS IN THE UNITED STATES, OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD NOT BE ALLOWED BY APPLICABLE LAW.
  
Aino Health AB (publ) ("Aino Health" or the "Company") has completed the Offer to the market to subscribe for shares in the Company for a total of 53.8 MSEK (the "Offer"), distributed on a share issue of 46.8 MSEK (the "Share Issue") and an Over-allotment of existing shares of 7.0 MSEK for stabilization activities (the "Over-allotment"). The Over-allotment including stabilization of the share price during 30 calendar days may imply that Aino Health will receive an addition of 7.0 MSEK through a share issue included in the Over-allotment option directed to Erik Penser Bank AB, after which the Company would receive up to 48.8 MSEK.  

The Offer attracted strong interest and was subscribed to about 206 percent, equivalent to 2.1 times the Offer. Due to the strong interest shares have been allocated to around 1 100 new shareholders among almost 4 000 applicants. First day of trading Aino Health's shares is scheduled for Friday December 16, 2016.

November 27, 2016, the Board of Directors in Aino Health published the decision to apply for listing of the Company's shares on Nasdaq First North, and in connection with the listing the Board of Directors decided to diversify the ownership through a Share Issue according to the Offer. The Offer consists of 1,800,000 newly issued shares and an Over-allotment of 270,000 existing shares as a part of the stabilization of the share price during 30 calendar days. The Company may receive an addition of 270,000 shares through the Over-allotment option directed to Erik Penser Bank as a part of the agreed stabilization of the share price.

The number of shares will increase from 3,622,770 to 5,422,770 through the Share Issue and up to 5,692,770 shares if the Over-allotment is fully exercised. The dilution for existing shareholders amounts to 33.2 percent and to a maximum of 36.2 percent if the Over-allotment option is fully exercised.

The Offer implies that the Company will be added around 1 100 new shareholders, after which the total number of shareholders will amount to approximately 1 200. The Company will meet the share distribution requirements on Nasdaq First North and the first day of trading is scheduled for Friday December 16, 2016.

The subscription period for the Offer expired on Thursday, December 8, 2016. A number of institutional partners and private investors have, before the initiated subscription period, undertaken to subscribe for shares in the Share Issue corresponding to approximately 31.9 MSEK, or about 86 percent of the Share Issue.

The Board of Directors in Aino Health has, in consultation with Erik Penser Bank, decided on the allotment of shares in the Offer, in which the objective has been to achieve a good distribution of the share to enable a regular and liquid trading on Nasdaq First North as well as achieving a desired strategic ownership base. The allotment decision will be obtained in the form of a contract note. Information will not be sent to those who have not been allotted shares.

After the Offer has been registered at the Swedish Companies Registration Office the total number of shares in Aino Health will increase by 1,800,000 shares from 3,622,770 shares to 5,422,770 shares. The share capital will increase by 4,500,000 SEK to 13,556,925 SEK. If the Over-allotment option is fully exercised, this implies an additional increase of 270,000 shares and an increase of the share capital of 675,000 SEK to 14,231,925 SEK.

"We are very pleased with the great interest we have had in Aino Health's IPO. While we have secured capital for our expansion into Europe with focus on Sweden and Germany as the first countries, we have received a large number of new shareholders. We are very happy for this and the legitimacy that our listing gives in various customer contacts", says Jyrki Eklund, CEO of Aino Health

Advisers
Erik Penser AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser in the Offer and listing on Nasdaq First North. Erik Penser AB is Certified Adviser to the Company.

Important information
Publication and distribution of this press release may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and follow such restrictions. The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares or another security in Aino Health.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or another country where such action requires further measures in addition to what follows from Swedish law or where this would contravene with laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Omission to follow this instruction may constitute a violation of the United States Securities Act of 1933 (the "Securities Act") in its present terms or applicable laws in other jurisdictions.

This information is such information that Aino Health AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at December 9 CET on 8:30 2016.

F or more information, please contact:
Jyrki Eklund, CEO
Phone: +358 40 042 4221
E-mail: jyrki.eklund@ainohealth.com

Cecilia Hollerup, Chairman of the Board of Directors
Phone: +46 70 829 33 36
E-mail: cecilia.hollerup@holleruppartners.se

About Aino Health
Aino Health operates within Corporate Health Management. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aino Health AB (publ) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

ICONOVO TECKNAR AVTAL MED MCMASTER UNIVERSITY AVSEENDE UTVECKLING AV VACCIN MOT TUBERKULOS15.10.2018 09:00Pressmeddelande

Det innovativa, Lundabaserade medicinteknikföretaget Iconovo AB (publ) meddelar i dag att bolaget har skrivit samarbetsavtal med McMaster University i Kanada. Avtalet avser utveckling av en torrpulverberedning av inhalerbart vaccin mot tuberkulos som ska användas i Iconovos unika engångsinhalator ICOone. Iconovo kommer att ingå i ett tvärvetenskapligt forsknings- och utvecklingsprojekt som syftar till att ta fram nästa generations virusbaserade vaccin i pulverform som är stabilt i rumstemperatur. Att kunna transportera vaccin utan krav på kylförvaring är en förutsättning för att snabbt och effektivt nå ut till de behövande. I det projekt som nu påbörjas kommer Iconovos unika engångsinhalator ICOone att användas som testplattform för att underlätta en framtida kommersialisering och storskalig tillverkning. Projektet beräknas pågå i tre år och finansieras bland annat av den kanadensiska staten (CIHR/NSERC). Tuberkulos förekommer i hela världen och är en av de tio vanligaste dödsorsakerna

Stillfront Group AB: Babil Games lanserar Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESSMEDDELANDE 4 oktober 2018 Babil Games, en del av Stillfront Group, ökar affärstillväxten och lanserar Arab Gamers' League, AGL Babil Games, ett dotterbolag till Stillfront Group, inleder partnerskap med kreativa byrån Grape Creations i Dubai och lanserar Arab Gamers' League (AGL), en ny studio som fokuserar på att lansera så kallade 'social casual games' till MENA-regionen. Babil Games kontrollerar 51% av AGL och Grape Creations övriga 49%. Babil Games är ansvarig för verksamheten och sourcing av spel medan Grape Creations ansvarar för marknadsföring och distribution. "Vi är mycket glada över vårt inledda partnerskap med Grape Creations gällande lanseringen av Arab Gamers' League. AGLs fokus är att lansera nästa generations 'social casual games' till MENA-regionen", säger MJ Fahmi, VD för Babil Games. Babil Games kommer att fortsätta att fokusera på MMO-strategispel. Antalet anställda i Babil Games har fördubblats under det senaste året och studion kommer att flytta till ett nytt

Stillfront Group AB: Babil Games launches Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESS RELEASE 4 October 2018 Babil Games, part of the Stillfront Group, accelerates business growth and launches Arab Gamers' League, AGL Babil Games, a subsidiary of Stillfront Group, is partnering with Dubai based creative agency Grape Creations to launch Arab Gamers' League (AGL), a new studio focused on bringing social casual games to the MENA-region. Babil Games controls 51% of AGL and Grape Creations the other 49%. Babil Games is head of the operations and the sourcing of the games while Grape Creations is responsible for marketing and distribution. "We are pleased to have Grape Creations as our partner for the launch of Arab Gamers League. In AGL we will focus on bringing the next generation of social casual games to the MENA region", says MJ Fahmi, CEO of Babil Games. Babil Games will continue to focus on strategy MMO games. The number of employees in Babil Games has doubled during the year and the studio will relocate to a new larger office in Amman, Jordan. "The expansion is

Hoylu AB: UNITED STATES AIR FORCE SELECTS HOYLU FOR COLLABORATION AND INNOVATION SOLUTIONS28.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 28, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Air Force has selected Hoylu Software and multiple large format HoyluWall systems as a digital workspace tool for workspace innovation and collaboration. Hoylu software will be used at multiple sites to create joined environments within the division. The order will be delivered in Q4 2018 and represents a deal value of SEK 3,670,000 in product and software revenue. The Air Force will use the system for training and education purposes, with the ability to connect users together and collaborate in real-time. The order represents a growing market for Hoylu software and services within the government sector. It is expected that Hoylu's solutions will continue to expand within this industry as innovative collaboration solutions are in demand. Hoylu's solutions and software offer new and exciting ways to learn and collaborate smarter, faster and more efficiently. Creat

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum